mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes

Author:

Jones Amanda K.1,Bajrami Besnik2ORCID,Campbell Morgan K.1,Erzurumluoglu Abdullah Mesut3ORCID,Guo Qiusha1,Chen Hongxing1,Zhang Xiaomei1,Zeveleva Svetlana1,Kvaskoff David2,Brunner Andreas-David2,Muller Stefanie3,Gathey Vasudha1,Dave Rajvee M.1,Tanner James W.1,Rixen Sophia4,Struwe Michel A.45,Phoenix Kathryn6,Klumph Kaitlyn J.1,Robinson Heather1,Veyel Daniel2,Muller Annkatrin2,Noyvert Boris3,Bartholdy Boris Alexander3,Steixner-Kumar Agnes A.3,Stutzki Jan37,Drichel Dmitriy37,Omland Steffen37,Sheehan Ryan8,Hill Jon9,Bretschneider Tom2,Gottschling Dirk10,Scheidig Axel J.5,Clement Bernd4,Giera Martin211,Ding Zhihao3,Broadwater John1,Warren Curtis R.1ORCID

Affiliation:

1. Department of Cardiometabolic Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA

2. Department of Drug Discovery Sciences, Discovery Science Technologies, Boehringer Ingelheim Pharma GmbH & Co., Biberach an der Riss, Germany

3. Department of Global Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co., Biberach an der Riss, Germany

4. Department of Pharmacy, Pharmaceutical Institute, Christian Albrechts University, Kiel, Germany

5. Department of Biology, Institute of Zoology-Structural Biology, Christian Albrechts University, Kiel, Germany

6. Department of Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA

7. Data Science Chapter, BI X GmbH, Ingelheim am Rhein, Germany

8. Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA

9. Department of Global Computational Biology and Digital Sciences, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA

10. Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co., Biberach an der Riss, Germany

11. The Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands

Abstract

Background: Mutations in the gene MTARC1 (mitochondrial amidoxime–reducing component 1) protect carriers from metabolic dysfunction–associated steatohepatitis (MASH) and cirrhosis. MTARC1 encodes the mARC1 enzyme, which is localized to the mitochondria and has no known MASH-relevant molecular function. Our studies aimed to expand on the published human genetic mARC1 data and to observe the molecular effects of mARC1 modulation in preclinical MASH models. Methods and Results: We identified a novel human structural variant deletion in MTARC1, which is associated with various biomarkers of liver health, including alanine aminotransferase levels. Phenome-wide Mendelian Randomization analyses additionally identified novel putatively causal associations between MTARC1 expression, and esophageal varices and cardiorespiratory traits. We observed that protective MTARC1 variants decreased protein accumulation in in vitro overexpression systems and used genetic tools to study mARC1 depletion in relevant human and mouse systems. Hepatocyte mARC1 knockdown in murine MASH models reduced body weight, liver steatosis, oxidative stress, cell death, and fibrogenesis markers. mARC1 siRNA treatment and overexpression modulated lipid accumulation and cell death consistently in primary human hepatocytes, hepatocyte cell lines, and primary human adipocytes. mARC1 depletion affected the accumulation of distinct lipid species and the expression of inflammatory and mitochondrial pathway genes/proteins in both in vitro and in vivo models. Conclusions: Depleting hepatocyte mARC1 improved metabolic dysfunction–associated steatotic liver disease–related outcomes. Given the functional role of mARC1 in human adipocyte lipid accumulation, systemic targeting of mARC1 should be considered when designing mARC1 therapies. Our data point to plasma lipid biomarkers predictive of mARC1 abundance, such as Ceramide 22:1. We propose future areas of study to describe the precise molecular function of mARC1, including lipid trafficking and subcellular location within or around the mitochondria and endoplasmic reticulum.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3